Anatomy of an Additional Information Letter: Triaging 510(k) Deficiencies Without Losing Your Slot

When the AI Letter Lands: What It Really Means

An Additional Information (AI) letter from FDA's Center for Devices and Radiological Health (CDRH) is not a rejection. It is not a death sentence for your 510(k). But it is a timed test -- and how your team responds in the next 180 days will determine whether your device reaches the market on schedule or cycles back to the starting line.

Under 21 CFR Part 807 and CDRH's current review process, an AI letter is FDA's formal mechanism for requesting supplemental information during the substantive review phase. Unlike a Refuse to Accept (RTA) finding, which halts the clock before review begins, an AI letter arrives after your submission has cleared acceptance review and been assigned to a reviewer. That distinction matters enormously: you still have a slot, and that slot is worth protecting.

The Clock Is Already Running

FDA's 510(k) review performance goals, established under the Medical Device User Fee Amendments (MDUFA), set a 90-day total review target for most standard 510(k)s. When CDRH issues an AI letter, the review clock is suspended -- but only temporarily. Under MDUFA V commitments (FDA's FY2023-2027 performance goals), FDA places the submission 'on hold' pending your response. Once you respond, the clock resumes.

Here is the operational reality that many sponsors miss: you have up to 180 days to respond before FDA may consider the submission withdrawn under 21 CFR 807.87(l). However, every day you delay is a day added to your total time-to-clearance. Treat the AI letter as a sprint, not a checkpoint.

Dissecting the Letter: Not All Deficiencies Are Equal

When your team receives the AI letter, resist the instinct to immediately draft responses. The first 24-48 hours should be spent in triage. AI letters typically contain a numbered list of deficiencies that fall into three functional categories:

• Documentation gaps: Missing predicate comparison tables, incomplete 510(k) summary, absent biocompatibility test reports per ISO 10993-1, or missing software documentation required under FDA's 2019 guidance on software functions. These are often straightforward to resolve if the data exists.
• Analytical deficiencies: Inadequate substantial equivalence arguments, insufficient performance testing rationale, or failure to address differences between your device and the predicate under the framework of 21 CFR 807.100(b). These require substantive scientific and regulatory work.
• Ambiguous or compound questions: Reviewer questions that bundle multiple concerns into a single item, or that signal a deeper conceptual disagreement about device classification or intended use. These are the highest-risk items and must be identified immediately.

Your triage output should be a clear matrix: which items can be resolved with existing data, which require new testing or analysis, and which may benefit from an informal FDA communication before you respond in writing.

Using Interactive Review to Your Advantage

CDRH's 2019 guidance on the 510(k) Program: Evaluating Substantial Equivalence explicitly supports interactive review as a tool to clarify deficiencies. If your AI letter contains ambiguous compound questions, requesting a brief teleconference with the reviewing branch is both appropriate and strategically sound. This is not pestering the reviewer -- it is using an FDA-sanctioned process to ensure your written response actually answers the question being asked.

Document every interaction meticulously. Any verbal clarification from CDRH should be summarized in a follow-up email to create a written record, which then anchors your formal response.

Structuring Your Response for Reviewer Efficiency

A well-structured AI response does more than answer questions -- it makes the reviewer's job easier, which builds goodwill and reduces the likelihood of a second AI letter. Best practices include:

• Mirror the exact numbering and language of each deficiency item from the original letter.
• Open each response with a one-sentence direct answer, followed by supporting rationale and referenced exhibits.
• Include a consolidated cross-reference table at the front of the response linking each deficiency to the specific section or exhibit where it is addressed.
• Flag any items where you are providing a 'partial response' pending test completion, and include a realistic timeline. Never overpromise on data delivery dates.

If new test reports are being generated, consider whether a phased response -- submitting documentary resolutions immediately while holding for performance data -- is appropriate. This keeps momentum visible to the reviewer and signals organizational competence.

When to Escalate Internally and Externally

A second AI letter is a serious signal. Under MDUFA V agreements, repeated AI cycles erode your standing in the review queue and can trigger escalation to a Not Substantially Equivalent (NSE) determination if unresolved issues touch the core of your substantial equivalence argument. If your first AI response generates a second round of deficiencies on the same topic, it is time to reassess your predicate strategy, your intended use language, or both -- before submitting again.

This is also the moment to critically evaluate whether independent regulatory counsel has reviewed your response strategy. Internal teams are often too close to the submission to identify where their arguments are not landing with a reviewer who is reading the device for the first time.

Protect the Slot. Accelerate the Clock.

An AI letter is a solvable problem -- but only if it is approached with discipline, speed, and regulatory precision. The sponsors who navigate AI letters successfully are those who triage before they write, communicate with FDA when the questions are unclear, and structure their responses to eliminate ambiguity rather than introduce more of it.

If your team has received an AI letter, is anticipating one, or wants to pressure-test a 510(k) submission before it reaches CDRH, the regulatory practice group at ADB Consulting and CRO Inc. is ready to help. Book a free discovery call at adbccro.com to discuss your submission strategy with our team and get a clear path forward.

For related guidance, see our 510(k) submission service.